Cyclophosphamide

Bone Sarcoma

Essen BiotechSmall moleculePhase 2Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

10 Active assets in the Bone Sarcoma cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Essen Biotech	Phase 2	B
TEONANACATL University Health Network, Toronto	Phase 2	CCC
Nivolumab M.D. Anderson Cancer Center	Phase 2	CCC
Ipilimumab M.D. Anderson Cancer Center	Phase 2	CCC
Lifileucel M.D. Anderson Cancer Center	Phase 2	CCC

View all 12 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

mycosis fungoidesDormant

BBB

Indicative ·

78 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.